Claire had been at her desk for maybe forty minutes when Maria appeared in her doorway, phone held up like a warrant.
"You need to see this before the Times calls you for comment."
It was the press release again, but this time the wire version — no embargo, live everywhere. Helix Therapeutics to merge with Vanterra Pharmaceuticals. The second paragraph had been rewritten since the version Maria forwarded the night before. It now read: *As part of the integration, CardioSense will be evaluated for strategic wind-down, with sunset targeted for Q3 of next year.*
"Sunset," Claire said.
"Eighteen months is a long trial," Maria said. "It's a short sunset."
Claire read it twice. Vanterra's press boilerplate sat above it like a fresh coat of paint over rot — *synergies, portfolio optimization, a shared commitment to patients.* Her hands had gone cold.
"Get Ethan."
He came in with a coffee he didn't drink and read the release over her shoulder, his breathing changing before his face did. When he straightened, he looked ten years older and entirely calm, which was worse.
"They're not killing the algorithm," he said. "They're killing the trial. Same outcome."
"Deborah's interview," Claire said. "Providence. She's supposed to be there at two."
"Cancel it," Maria said.
"No." Claire stood, already reaching for her coat. "Move it up. Get her on the phone now. If Vanterra wants to call this integration, I want to know exactly what they think they're integrating — and who decided those four sites were expendable before the merger even closed."
Maria's eyebrows went up. "You think it's connected."
"I think it's all the same hand." Claire looked at Ethan. "The anonymous texts. The dropped sites. Now this. Somebody decided a year ago that the confirmatory cohort should be small enough to fail."
Ethan set the coffee down, untouched. "Then we don't fight the merger. We fight the wind-down."
They did it in the conference room on the fourth floor because it had a window and the window had good light, and because Claire had learned in the last year that light mattered when you were asking frightened people to stand up in public.
The patient advisory group filled eleven of the sixteen chairs. Some had driven in from Worcester, one woman from Providence with her daughter, one man in his sixties who had a CardioSense device in his chest and a printout of the press release in his lap that he kept smoothing flat with his thumb as if it were a photograph.
Deborah spoke first, from speakerphone, her voice tinny and precise: the Providence coordinator had confirmed that the site had been flagged for "resource reallocation" three weeks before the merger was announced. No clinical justification on record. The PI, Dr. Okonkwo, had filed a protest that had never been answered.
"Three weeks," Ethan said quietly.
"Before the deal was public," Claire said. "So either Vanterra was already inside, or Helix executives were clearing the runway for a sale."
The man with the printout raised his hand like he was in church. "What does sunset mean. In plain words."
"It means they stop supporting the device," Claire said. "No software updates. No safety monitoring. And the trial that proves the corrected algorithm works — the one that would keep it on the market for everyone after us — gets shelved before it finishes."
"So they bury it."
"They try."
He smoothed the paper flat again. "I buried my wife in 2019," he said. "CardioSense missed her arrhythmia. I signed on to this group so the next woman's husband wouldn't have to." He looked around the table. "I'll stand in front of a camera. I don't care who sees me."
The room changed after that. It wasn't a decision so much as a tide. The woman from Providence asked if her daughter could speak too. Someone else wanted to know whether the board's exoneration report could be quoted. Deborah, on speaker, said she'd have written statements ready by morning.
Claire stood at the head of the table with a marker and the whiteboard and started writing names, dates, and a list of who would call which reporter. Halfway through, she caught Ethan watching her, and there was something in his face she hadn't seen before — not the old guarded grief, but a steady, forward-leaning attention, like a man who'd stopped bracing for the fall.
He took the marker from her when her list ran out of room. Their fingers touched, nothing more, and he wrote the next three names himself.
The statement went out at ten the next morning under the advisory group's letterhead, with sixty-one signatures. By noon it was in the Globe. By two, two of the four dropped-site PIs had emailed Deborah asking how to join.
The company's response came at four: a one-paragraph email from corporate communications thanking stakeholders for their engagement and reiterating the parties' commitment to a thoughtful evaluation of the CardioSense portfolio.
Claire read it aloud in the hallway outside the lab, and Ethan laughed — a real laugh, short and surprised, the kind she almost never got from him.
"Thoughtful evaluation," he said. "That's Kessler's old language. He's still in the building somewhere, whispering."
"They can't fire a whole patient community."
"They can try." He looked at her. "We've got maybe six weeks before the proxy vote. If the outcry is loud enough, the institutional investors get nervous, and a delayed integration is a real possibility."
"Then we use the six weeks."
"On what?"
She'd been thinking about it since the meeting, through the sleepless hours of the previous night, and she knew he'd already arrived at the same answer — she could see it in the way he was standing, squared up to her, waiting to be told he was right.
"An independent study," she said. "If they shelve the trial, we run our own. Funded outside the company, published outside the company, the gender variables locked in so nobody can quietly walk them back."
Ethan was quiet. Then: "That's a year of work. Minimum."
"I know."
"And they'll fight it. Subpoenas, IP claims, the whole thing."
"I know that too."
He nodded, slowly, and something eased in his shoulders — the way he'd looked in the cemetery, but turned inside out, the guilt rerouted into purpose. "Okay," he said.
Just that. *Okay.*
Behind them the lab hummed, and the city darkened past the window, and somewhere north of Boston the news was already moving through the wires toward tomorrow.